ArticleStem cells translational medicine2020
Translating intracarotid artery transplantation of bone marrow-derived NCS-01 cells for ischemic stroke: Behavioral and histological readouts and mechanistic insights into stem cell therapy.
Article in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- The Role of IL-6 in Ischemic Stroke.Biomolecules · 2025Review
- Neuroinflammation and acute ischemic stroke: impact on translational research and clinical care.Frontiers in surgery · 2025Review
- Article
- Priming and Combined Strategies for the Application of Mesenchymal Stem Cells in Ischemic Stroke: A Promising Approach.Molecular neurobiology · 2024Review
- An update on stem cell therapy for stroke patients: Where are we now?Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Review
- Multinuclear MRI Reveals Early Efficacy of Stem Cell Therapy in Stroke.Translational stroke research · 2023Article
- Getting the guts to expand stroke treatment: The potential for microbiome targeted therapies.CNS neuroscience & therapeutics · 2023Review
- Probing Interleukin-6 in Stroke Pathology and Neural Stem Cell Transplantation.International journal of molecular sciences · 2022Review
- Neuroinflammation, Stem Cells, and Stroke.Stroke · 2022Review
- Human Mesenchymal Stem/Stromal Cells in Immune Regulation and Therapy.Stem cells translational medicine · 2022Review
- Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications.Stem cells international · 2022Review
- Mesenchymal Stem Cells for Neurological Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Bone Marrow-Derived NCS-01 Cells Advance a Novel Cell-Based Therapy for Stroke.International journal of molecular sciences · 2020Review
- Translating intracarotid artery transplantation of bone marrow-derived NCS-01 cells for ischemic stroke: Behavioral and histological readouts and mechanistic insights into stem cell therapy.Stem cells translational medicine · 2020Article
- Mesenchymal stem cells injected into carotid artery to target focal brain injury home to perivascular space.Theranostics · 2020Article
- Enhancing Brain Plasticity to Promote Stroke Recovery.Frontiers in neurology · 2020Review
- Bone marrow-derived NCS-01 cells for ischemic stroke.Brain circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study used in vitro and in vivo stroke models to demonstrate the safety, efficacy, and mechanism of action of adult human bone marrow-derived NCS-01 cells. Coculture with NCS-01 cells protected primary rat cortical cells or human neural progenitor cells from oxygen glucose deprivation. Adult rats that were subjected to middle cerebral artery occlusion, transiently or permanently, and subsequently received intracarotid artery or intravenous transplants of NCS-01 cells displayed dose-dependent improvements in motor and neurological behaviors, and reductions in infarct area and peri-infarct cell loss, much better than intravenous administration. The optimal dose was 7.5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.